931 related articles for article (PubMed ID: 34787345)
1. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
[TBL] [Abstract][Full Text] [Related]
2. A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
Ahearn AJ; Thin Maw T; Mehta R; Emamaullee J; Kim J; Blodget E; Kahn J; Sher L; Genyk Y
Transplantation; 2022 Feb; 106(2):e153-e157. PubMed ID: 34519680
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
[TBL] [Abstract][Full Text] [Related]
5. Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.
Bachmann F; Budde K; Suttorp N; Lingscheid T; Stegemann MS; Osmanodja B; Schrezenmeier E; Duettmann W; Weber U; Naik M; Lehner LJ; Kahl A; Duerr M; Eckardt KU; Waiser J; Choi M; Halleck F
Transpl Int; 2022; 35():10109. PubMed ID: 35431640
[No Abstract] [Full Text] [Related]
6. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract][Full Text] [Related]
9. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.
Yetmar ZA; Bhaimia E; Razonable RR
Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
11. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.
Kutzler HL; Kuzaro HA; Serrano OK; Feingold A; Morgan G; Cheema F
Transpl Infect Dis; 2021 Oct; 23(5):e13662. PubMed ID: 34081820
[TBL] [Abstract][Full Text] [Related]
12. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
[TBL] [Abstract][Full Text] [Related]
13. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.
Candel FJ; Salavert M; Lorite Mingot D; Manzano Crespo M; Pérez Portero P; Cuervo Pinto R
Rev Esp Quimioter; 2023 Aug; 36(4):380-391. PubMed ID: 37089055
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.
Yetmar ZA; Beam E; O'Horo JC; Ganesh R; Bierle DM; Brumble L; Seville MT; Razonable RR
Open Forum Infect Dis; 2021 Jun; 8(6):ofab255. PubMed ID: 34631921
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
Yetmar ZA; Yao JD; Razonable RR
J Med Virol; 2023 Jun; 95(6):e28885. PubMed ID: 37334976
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
17. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
[TBL] [Abstract][Full Text] [Related]
19. Is the Omicron variant truly less virulent in solid organ transplant recipients?
Anjan S; Khatri A; Viotti JB; Cheung T; Garcia LAC; Simkins J; Loebe M; Phancao A; O'Brien CB; Sinha N; Ciancio G; Vianna RM; Andrews D; Abbo LM; Guerra G; Natori Y
Transpl Infect Dis; 2022 Dec; 24(6):e13923. PubMed ID: 35915957
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
